Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study

Pediatric Hematology and Oncology

Volumn 28, Issue 7, 2011, Pages 556-570

  Felix, Francisco Helder Cavalcante ^a   Trompieri, Nadia Mendonça ^a   De Araujo, Orlandira Leite ^a   Da Trindade, Karine Martins ^a   Fontenele, Juvenia Bezerra ^b  

^a Hospital Infantil Albert Sabin   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Brain tumor; Epigenetic drug effects; Survival; Valproate

Indexed keywords

CARBOPLATIN; COTRIMOXAZOLE; DEXAMETHASONE; NAPROXEN; OMEPRAZOLE; RANITIDINE; VALPROIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ANTIANGIOGENIC ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRAIN EDEMA; BRAIN STEM TUMOR; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIENCEPHALON; EPENDYMOMA; FOLLOW UP; GLIOBLASTOMA; GLIOSIS; HUMAN; INFANT; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; OTORRHEA; PNEUMOCYSTIS PNEUMONIA; PONTINE GLIOMA; PRESCHOOL CHILD; PROGNOSIS; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER STAGING; COHORT ANALYSIS; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 80053085577     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.563774     Document Type: Article

References (46)

1. Gottardo N, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol. 2008;23:1149-1159.
2. Grill J, Bhangoo R. Recent development in chemotherapy of paediatric brain tumours. Curr Opin Oncol. 2007;19:612-615. (Pubitemid 47508870)
3. Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10:258-266.
4. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8:696-705. (Pubitemid 47189085)
5. Wolf JEA, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pe-diatric high-grade glioma after gross total resection: results of the HIT-gBM-c protocol. Cancer. 2010;116:705-712.
6. Dufner PK, Horowitz ME, Krischer JP, et al. Te treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999;1:152-161.
7. Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today? Pediatr Neurosurg. 2007;43:192-201. (Pubitemid 46558914)
8. Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest. 2006;24:77-81. (Pubitemid 43247277)
9. Jenkin RD, Boesel C, Ertel I, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66:227-233. (Pubitemid 17027880)
10. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tip-ifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110:2535-2541. (Pubitemid 350174941)
11. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20:3431-3437.
12. Fink KL. Chemotherapy and Anti-Epileptic Drug Interactions. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy. San Diego: Academic Press; 2006:44-57.
13. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489-1494. (Pubitemid 39578871)
14. Henry T. Te history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37(Suppl 2):5-16.
15. Cotariu D, Zaidman J. Valproic acid and the liver. Clin Chem. 1988;34:890-897.
16. van Breemen M, Wilms E, Vecht C. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421-430. (Pubitemid 46551867)
17. Tremont-Lukats I, Ratilal B, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;(2):CD004424.
18. da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH. Pediatric acute promyelocytic leukemia: all-trans-retinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol. 2008;30:387-390. (Pubitemid 351643464)
19. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11:850-856. (Pubitemid 23146078)
20. Freeman CR, Kepner J, Kun LE, et al. A detrimental efect of a combined chemotherapy-radiotherapy approach in children with difuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys. 2000;47:561-564. (Pubitemid 30317471)
21. Masoudi A, Elopre M, Amini E, et al. Infuence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437-2442.
22. Goto M, Ohnishi C, Yamashina H, et al. Efect of valproic acid on pharmacokinetics of active metabolites of cyclophosphamide in mice. J Pharmacobiodyn. 1987;10:8-14. (Pubitemid 17017251)
23. Bourg V, Lebrun C, Chichmanian R, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol. 2001;12:217-219. (Pubitemid 32223871)
24. Wolf J, Kramm C, Kortmann R, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008;90:309-314.
25. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007;8:383-393.
26. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid asepigeneticcancer drug: preclinical, clinical and transcriptional efects on solid tumors. Cancer Treat Rev. 2008;34:206-222.
27. Driever P, Knü pfer M, Cinatl J, et al. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr. 1999;211:323-328.
28. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defnes a novel class of HDAC inhibitors inducing diferentiation of transformed cells. EMBO J. 2001;20:6969-6978. (Pubitemid 34062289)
29. Munster P, Marchion D, Bicaku E, et al. Clinical and biological efects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epiru-bicin/FEC. Clin Cancer Res. 2009;15:2488-2496.
30. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008;14:6296-6301.
31. Dutta S, Cloyd J, Granneman G, et al. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res. 2003;53:29-38. (Pubitemid 36170168)
32. Burgess R, Jenkins R, Zhang Z. Epigenetic changes in gliomas. Cancer Biol Ther. 2008;7:1326-1334.
33. Furchert S, Lanvers-Kaminsky C, Juü rgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer. 2007;120:1787-1794. (Pubitemid 46399367)
34. Beńitez J, Arregui L, Cabrera G, et al. Valproic acid induces polarization, neuronal-like diferentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience. 2008;156:911-920.
35. Das C, Aguilera D, Vasquez H, et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol. 2007;85:159-170. (Pubitemid 47629397)
36. Chinnaiyan P, Cerna D, Burgan W, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res. 2008;14:5410-5415.
37. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol. 2005;83:429-437. (Pubitemid 41626761)
38. Valentini A, Gravina P, Federici G, et al. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther. 2007;6:185-191. (Pubitemid 46641621)
39. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992;10:249-256.
40. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic efects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis. 2009;12:81-90.
41. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573-581. (Pubitemid 41697342)
42. Bocci G, Francia G, Man S, et al. Trombospondin 1, a mediator of the antiangiogenic efects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA. 2003;100:12917-12922. (Pubitemid 37340000)
43. Perez J, Pardo J, Gomez C. Vincristine-an efective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41:197-199. (Pubitemid 34557083)
44. Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103:2636-2642. (Pubitemid 40800545)
45. Bijman MN, van Nieuw Amerongen GP, Laurens N, et al. Microtubule- targeting agents inhibit angio-genesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006;5:2348-2357. (Pubitemid 44530472)
46. Michaelis M, Michaelis UR, Fleming I, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004;65:520-527. (Pubitemid 38264019)